Thermo Fisher Scientific
In this webinar, learn how mass spectrometry has been used to identify more than 500 unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from a panel of healthy donors. This work by researchers at Eli Lilly and Co. represents the most precise and comprehensive HLA-II immunopeptidomic investigation with SARS-CoV-2 spike glycoprotein and allows for detailed analysis of features, which may aid crucial vaccine development.
Michael Knierman, Senior Research Scientist, Eli Lilly and Co.
Michael Knierman is currently working in the Mass Spec/Antibody Engineering group in the Laboratory for Experimental Medicine at Eli Lilly.
* Required field
Don't have an account ?